ERBB3 and cancer: ERBB3 activating alterations were detected in 1.8% (n = 7,571) of tumors in the overall cohort and were most prevalent in small bowel (7.7%), bladder (6.1%), urinary tract (4.6%), uterine (4.3%), and GEC (4.1%) cancers (Fig. 1B).